Page 3 - Paresthesia News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ChemoCentryx said it plans to price its new medicine at an annual cost of $150,000 to $200,000 for US patients.

University of pennsylvaniaUnited statesPetera merkelDrug administrationArthritis advisory committee meetingPerelman school of medicineChemocentryx incCentryx incNew england journalBirmingham vasculitis activity scorePerelman schoolAdvisory committee meetingUs food and drug administrationNited states food and drug administrationAutoimmune diseaseOint inflammation